WDA (Wholesale Distribution Authorisation)

ProPharma can assisst with obtaining MHRA WDA Licence

Our WDA Expertise

ProPharma is a leader in assisting clients to navigate the complex landscape of Wholesale Distribution Authorisation (WDA) requirements. Our expertise encompasses the full spectrum of services needed to obtain and maintain a WDA, ensuring compliance with the stringent regulations set by the Medicines and Healthcare products Regulatory Agency (MHRA) and the Veterinary Medicines Directorate (VMD). We provide comprehensive support, including writing and refining Quality Management Systems (QMS), conducting thorough gap analyses, and performing vendor audits. Our team of experienced professionals delivers tailored training programs for employees and conducts mock inspections to prepare clients for regulatory reviews. With our robust understanding of Good Distribution Practice (GDP) principles and guidelines, ProPharma ensures that our clients meet all the necessary standards to achieve and sustain their WDA status. 

ProPharma's Experience with WDA Applications

ProPharma has a proven track record of successfully guiding clients through the WDA application process and beyond. Our extensive experience includes supporting clients in applying for both human and veterinary WDA licenses, providing contract Responsible Persons (RP), Responsible Person import (RPi), and Wholesale Qualified Persons (WQP). We can also provide contract Qualified Person (QP) support to our clients either on their Manufacturers Import Authorisation (MIA) or under ProPharma’s MIAs. We have developed and implemented numerous Quality Management Systems (QMS) tailored to our clients' specific needs, ensuring compliance and readiness for regulatory inspections. Our team has fronted regulatory inspections on behalf of clients, delivering post-inspection remedial support to address any issues identified. With a commitment to excellence, ProPharma's experienced professionals have consistently enabled clients to achieve their WDA goals, maintaining the highest standards of quality and compliance.

Document search icon

What is a WDA (Wholesale Distribution Authorisation)?

What is a WDA (Wholesale Distribution Authorisation)?

Decentralized Clinical Trials icon

WDA (H) and (V)

WDA (H) and (V)

Quality & Compliance icon

Who needs a WDA?

Who needs a WDA?

Compliance

Requirements prior to applying for a WDA (H) or WDA (V)

Requirements prior to applying for a WDA (H) or WDA (V)

What is a WDA (Wholesale Distribution Authorisation)?

A wholesale distribution authorisation (WDA) is a legal requirement for any company that stores or distributes human or veterinary medicines in the UK.  A WDA is also known as a “wholesale dealer licence” or a “wholesale dealer authorisation”, and it replaces the previous term of wholesale dealers’ licence (often called WDL or WL).

There are different types of WDA available depending on the nature and scope of the distribution activities.

A WDA can cover both licensed and unlicensed medicines, as well as investigational medicinal products (IMPs) for use in clinical trials, depending on the scope applied for in the application.

For example, a WDA (H) is for medicines for human use, a WDA (V) is for medicines for veterinary use, and a WDA (IMP) is for investigational medicinal products.

Woman using a dropper into a bottle

WDA (H) and (V)

A WDA (H) is issued by the Medicines and Healthcare products Regulatory Agency (MHRA), which is the UK authority responsible for ensuring the quality, safety, and efficacy of human medicines. 

A WDA (V) is issued by the Veterinary Medicines Directorate, which is the UK authority responsible for ensuring the quality, safety, and efficacy of veterinary medicines. 

WDAs will vary as to the specific conditions or restrictions attached to them, such as 

  • activities covered – procurement, holding, supply, export, other activities 
  • products with additional requirements – medical gases, cold chain, narcotic or psychotropic products, products derived from blood, immunological products, radiopharmaceuticals. 
  • legal category of products - prescription only medicine (POM) pharmacy sale (P), general sales list (GSL), controlled drugs (CD) which also require the appropriate Home Office licence issued under the Misuse of Drugs Regulations 2001, Traditional Herbal medicinal Products (THMP), Homeopathic products. 
  • source of products - UK, EU or non-UK/EU manufactured. 
  • destination of products – UK domestic market, or export to EU or non -EU countries.
Woman technician looking into microscope

Who needs a WDA?

Anyone who procures, stores, or supplies medicines to anyone other than the patient using the medicine needs a WDA (H), and for veterinary products a WDA (V). This includes wholesalers, distributors, importers and exporters.

Online retailers of medicines do not require a wholesale authorisation if they are supplying the end user in quantities of less than 3 months’ supply. Brokers required a broker registration, which permits negotiation on trades, but not the ability to buy, sell or hold.

Confident worker woman looking at camera

Requirements prior to applying for a WDA (H) or WDA (V)

Prior to applying for a WDA (H) application, one needs to demonstrate compliance with the Human Medicines Regulations (2012), GDP principles and guidelines which cover the quality system, personnel, premises and equipment, documentation, operations, complaints, recalls, returns, falsified medicines, outsourced activities, self-inspections, transportation, and brokers.

These requirements are addressed in the 10 Chapters of the EU GDP Guidelines (2013/C 343/01).

To apply for a WDA (H), one needs to complete an online application form and submit it to the MHRA, along with the required accompanying documents and fees.

The MHRA will conduct a GDP inspection of the site within 90 days of a validated application before granting or renewing a licence and will also conduct periodic risk-based inspections to monitor ongoing compliance.

The process for applying for a WDA (V) is similar to that for a WDA (H), except that the application and inspection is via the Veterinary Medicines Directorate (VMD).

Group of people in lab coats holding devices smiling at camera

Responsibilities of a WDA holder

The WDA holder has a number of responsibilities and obligations to ensure the compliance with the GDP standards and the WDA conditions. Some of these include:  

  • Implementing and maintaining a quality management system (QMS) that meets the GDP requirements
  • Appointing a responsible person (RP) for GDP for a WDA (H) or a wholesale dealer qualified person (WQP) for a WDA (V), who oversees and ensures the compliance with the GDP principles and guidelines. The exact requirements for an RP/WQP are set in the national legislation, but in general, it is a degree in Natural Science/Pharmacy and relevant experience in GDP is required.
  • Following Brexit in January 2020 a new role of Responsible Person import (RPi) was introduced to oversee the certification of imported EU Qualified Person certified UK stock into the UK under a WDA (H).
  • Ensuring that the personnel involved in the distribution activities are adequately trained and competent
  • Verifying the authenticity and quality of the products before they are procured, stored, or supplied
  • Managing the risks associated with the distribution activities, such as deviations, complaints, recalls, and falsified medicines
  • Conducting self-inspections and audits of the suppliers and customers
  • Ensure that all storage warehouses and transportation vehicles are temperature mapped
  • Ensure that all storage warehouses have adequate security, are clean and free from contamination, designated areas for receipt of medicines, appropriate temperature-controlled areas such as ambient, fridges, freezers, and appropriate pest controls in place
  • Keeping accurate and up-to-date records of all the distribution activities
  • Have proper stock rotation and carry out a detailed stock audit at least once a year
  • Store and transport medicines in line with each products storage and transportations conditions as listed in the Marketing Authorisation (MA)
  • Cooperating with the MHRA/VMD and providing them with the necessary information and documentation
  • Reporting any suspected adverse reactions or quality defects to the MHRA/VMD
  • Have an emergency recall plan; a system in place that if a recall of the product is required then the company is readily able to identify and contact all their customers
  • Notifying the MHRA/VMD of any changes to the WDA (H)/WDA (V) details or activities
  • Renewing the licence every five years

How can ProPharma assist you in obtaining a WDA?  

PropPharma has assisted many clients to obtain their own WDA (H) and WDA (V) including the following activities:

  • writing their Quality Management System (QMS)
  • conducting a gap analysis on their current QMS and undertaking remediation support
  • auditing their vendors
  • GDP training of employees
  • undertaking mock inspections and recalls
  • applying for their WDA licenses
  • providing contract Responsible Person’s (RP), responsible Person import (RPi) and contract Wholesale Qualified Person’s (WQP)
  • providing contract quality managers
  • fronting the regulatory inspection for the client
  • providing post inspection remedial support

ProPharma has extensive experience in developing Quality Management Systems (QMS) to support clients to apply for their own WDA (H) or WDA (V) and overseeing their regulatory inspection.

We have registered Qualified Persons and Responsible Persons who are eligible to act a RP, RPi or WQP on our clients’ WDA (H) or WDA (V).

Business professionals smiling at a desk reviewing data

ProPharma WDA Licence Assistance

If you need help obtaining a WDA, connect with our experts today. We are here to discuss your current issues and concerns and provide you with a bespoke solution.

WDA Experts

  • David Crome Bio Photo

    David Crome

    Managing Director, Quality & Compliance UK & India

    View Bio

  • Alexis O’temro Bio Photo

    Alexis O’temro

    Associate Director, Quality & Compliance

  • Ruth Buchanan Bio Photo

    Ruth Buchanan

    Associate Director, Quality & Compliance

    View Bio

  • Saket Jadhav Bio Photo

    Saket Jadhav

    Quality Assurance Consultant

    View Bio

With over 45 years of experience in the pharmaceutical industry, David Crome has worked with both branded and generic multinational companies, including a decade in consultancy. His career has spanned most functions in the industry, covering the entire product lifecycle: R&D, regulatory, production, QA, supply chain, auditing (with over 150 audits undertaken), marketing, setting up new businesses, and assisting clients in attaining EU/UK GMP certification. David has participated in over 60 regulatory inspections conducted by various agencies, such as the MHRA, HPRA, EMA, SUKL, USFDA, SAHPRA, and Anvisa, across England, Ireland, Argentina, Bangladesh, the Czech Republic, and India.

Ruth Buchanan has over 28 years of experience in the pharmaceutical industry, working with both branded multinationals and small generic manufacturing and virtual pharmaceutical companies, including six years in consultancy. She has worked within the technical and quality functions of the industry, focusing on solid dose, respiratory, creams, and liquids, with human and veterinary medicines. Her expertise includes product transfer, auditing, and assisting clients in attaining EU/UK GMP certification. Ruth has been named as a Qualified Person, Responsible Person, and Responsible Person (Import). She has experience hosting and leading regulatory inspections by agencies such as the MHRA, VMD, and FDA for both existing and new manufacturing licenses and WDA(H).

Saket Jadhav has over 13 years of experience in the pharmaceutical industry, working in both regulatory and quality functions, including five years in consultancy. He has been involved in technical and quality roles covering solid dose and parallel import, technology transfer, auditing, and assisting clients in obtaining WDA(H) approval. Saket has also served as a Responsible Person and Responsible Person (Import). He has successfully hosted MHRA audits for both new and existing MIA and WDA(H) licenses.

News & Insights

WHO Issues Guidance on Antibiotic Pollution Control

December 19, 2024

WHO Issues Guidance on Antibiotic Pollution Control

WHO issues guidance to control antibiotic pollution from manufacturing, addressing environmental and global health impacts of antimicrobial resistance.

Nonclinical Drug Development: FDA Recommendations for Confirming an Ames Positive Finding

December 18, 2024

Nonclinical Drug Development: FDA Recommendations for Confirming an Ames Positive Finding

Explore FDA's recommendations on follow-up testing for Ames-positive drugs to support first-in-human clinical trials. Learn how to navigate FDA regulations and ensuring successful product development.

Navigating Market Access & Reimbursement Strategy for Medical Devices in Europe

December 17, 2024

Navigating Market Access & Reimbursement Strategy for Medical Devices in Europe

Explore the importance of market access and reimbursement strategies for medical devices and in vitro diagnostics (IVDs) in Europe. Learn how early planning and the new European HTAR can enhance the...

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Names Dawn Sherman Chief Executive Officer

September 30, 2024

ProPharma Names Dawn Sherman Chief Executive Officer

Dawn Sherman rejoins ProPharma as CEO, bringing nearly 30 years of industry experience to lead the regulatory, clinical, and compliance services provider.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

ProPharma Receives 2024 CRO Leadership Award

June 13, 2024

ProPharma Receives 2024 CRO Leadership Award

ProPharma wins 2024 CRO Leadership Award for exceeding expectations in key categories, solidifying its position as a top global research consulting organization in the life sciences industry.

Infographic The Cost of Poor Project Management - ProPharma

June 10, 2022

The Cost of Poor Project Management

Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...

Infographic Successfully Passing MHRA Inspections for Overseas Manufacturing Sites - ProPharma

August 31, 2022

Successfully Passing MHRA Inspections for Overseas Manufacturing Sites

ProPharma offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma’s Compliance and Quality team completed the first on-site...

Infographic Navigating the Generic Drug Application and Approval Process - ProPharma

October 4, 2021

Navigating the Generic Drug Application and Approval Process

Navigating the generic drug application and approval process can be challenging. From pre-filing through post-approval, find out exactly what needs to be done for your Abbreviated New Drug...

News & Insights

ProPharma Appoints Brian Tuttle as Chief Financial Officer

October 21, 2024

ProPharma Appoints Brian Tuttle as Chief Financial Officer

ProPharma appoints Brian Tuttle as CFO to drive financial strategy and accelerate global growth, leveraging his 20 years of life sciences industry experience.

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Names Dawn Sherman Chief Executive Officer

September 30, 2024

ProPharma Names Dawn Sherman Chief Executive Officer

Dawn Sherman rejoins ProPharma as CEO, bringing nearly 30 years of industry experience to lead the regulatory, clinical, and compliance services provider.

Previous Post Arrow Next Post Arrow
ProPharma Receives 2024 CPHI Regulatory and Compliance Award

October 9, 2024

ProPharma Receives 2024 CPHI Regulatory and Compliance Award

ProPharma wins CPHI Pharma Award for excellence in regulatory and compliance innovation, enhancing efficiency and accelerating market access for life-saving therapies.

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

September 24, 2024

ProPharma Honored in the 2024 Clinical Trials Excellence Awards

ProPharma honored with Clinical Trials Excellence Award 2024, recognizing their outstanding contributions in the pharmaceutical industry.

ProPharma Receives 2024 CRO Leadership Award

June 13, 2024

ProPharma Receives 2024 CRO Leadership Award

ProPharma wins 2024 CRO Leadership Award for exceeding expectations in key categories, solidifying its position as a top global research consulting organization in the life sciences industry.

Previous Award Arrow Next Award Arrow
WHO Issues Guidance on Antibiotic Pollution Control

December 19, 2024

WHO Issues Guidance on Antibiotic Pollution Control

WHO issues guidance to control antibiotic pollution from manufacturing, addressing environmental and global health impacts of antimicrobial resistance.

Nonclinical Drug Development: FDA Recommendations for Confirming an Ames Positive Finding

December 18, 2024

Nonclinical Drug Development: FDA Recommendations for Confirming an Ames Positive Finding

Explore FDA's recommendations on follow-up testing for Ames-positive drugs to support first-in-human clinical trials. Learn how to navigate FDA regulations and ensuring successful product development.

Navigating Market Access & Reimbursement Strategy for Medical Devices in Europe

December 17, 2024

Navigating Market Access & Reimbursement Strategy for Medical Devices in Europe

Explore the importance of market access and reimbursement strategies for medical devices and in vitro diagnostics (IVDs) in Europe. Learn how early planning and the new European HTAR can enhance the...

Previous Post Arrow Next Post Arrow
Infographic The Cost of Poor Project Management - ProPharma

June 10, 2022

The Cost of Poor Project Management

Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...

Infographic Successfully Passing MHRA Inspections for Overseas Manufacturing Sites - ProPharma

August 31, 2022

Successfully Passing MHRA Inspections for Overseas Manufacturing Sites

ProPharma offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma’s Compliance and Quality team completed the first on-site...

Infographic Navigating the Generic Drug Application and Approval Process - ProPharma

October 4, 2021

Navigating the Generic Drug Application and Approval Process

Navigating the generic drug application and approval process can be challenging. From pre-filing through post-approval, find out exactly what needs to be done for your Abbreviated New Drug...

Previous Resource Arrow Next Resource Arrow